Skip to content

Vor Biopharma VOR Change in Other Assets

Change in Other Assets at other companies

Amgen logo
AmgenAMGN
-$8M-104%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$2.33M+21.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$662K+138%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$287K-79.6%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$228K+90.9%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$949K-116%

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's change in other assets?
Vor Biopharma (VOR) reported change in other assets of $6.36M in Q1 2026.
How has Vor Biopharma's change in other assets changed year-over-year?
Vor Biopharma's change in other assets increased by 2652.8% year-over-year, from $231K to $6.36M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.